CIPLA Stock Overview
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for CIPLA from our risk checks.
Cipla Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹1,488.45 |
52 Week High | ₹1,519.00 |
52 Week Low | ₹852.00 |
Beta | 0.37 |
1 Month Change | 3.31% |
3 Month Change | 20.32% |
1 Year Change | 71.74% |
3 Year Change | 92.59% |
5 Year Change | 182.52% |
Change since IPO | 46,025.84% |
Recent News & Updates
Is Cipla (NSE:CIPLA) Using Too Much Debt?
Feb 14Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Jan 26Recent updates
Is Cipla (NSE:CIPLA) Using Too Much Debt?
Feb 14Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Jan 26Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely
Jan 08Is Cipla (NSE:CIPLA) Using Too Much Debt?
Nov 15Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Oct 05Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?
Aug 04Is Cipla (NSE:CIPLA) A Risky Investment?
Mar 24A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)
Mar 06Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet
Dec 11Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)
Aug 19Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00
Jul 30Cipla (NSE:CIPLA) Could Easily Take On More Debt
Jul 14If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity
Jul 01Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 30Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Mar 23Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Dec 18Calculating The Fair Value Of Cipla Limited (NSE:CIPLA)
Dec 05Is Cipla (NSE:CIPLA) Using Too Much Debt?
Oct 27If You Like EPS Growth Then Check Out Cipla (NSE:CIPLA) Before It's Too Late
Sep 16Cipla Limited (NSE:CIPLA) Shares Could Be 23% Above Their Intrinsic Value Estimate
Aug 31It's Unlikely That Cipla Limited's (NSE:CIPLA) CEO Will See A Huge Pay Rise This Year
Aug 18Cipla (NSE:CIPLA) Could Easily Take On More Debt
Jul 12Are Cipla Limited (NSE:CIPLA) Investors Paying Above The Intrinsic Value?
May 28Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?
Mar 21Here's Why I Think Cipla (NSE:CIPLA) Is An Interesting Stock
Mar 08Do Fundamentals Have Any Role To Play In Driving Cipla Limited's (NSE:CIPLA) Stock Up Recently?
Feb 23Have Insiders Sold Cipla Limited (NSE:CIPLA) Shares Recently?
Feb 11Shareholder Returns
CIPLA | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -1.0% | -2.6% | -3.7% |
1Y | 71.7% | 65.3% | 44.0% |
Return vs Industry: CIPLA exceeded the Indian Pharmaceuticals industry which returned 65.3% over the past year.
Return vs Market: CIPLA exceeded the Indian Market which returned 44% over the past year.
Price Volatility
CIPLA volatility | |
---|---|
CIPLA Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 6.1% |
Market Average Movement | 6.7% |
10% most volatile stocks in IN Market | 10.2% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: CIPLA has not had significant price volatility in the past 3 months.
Volatility Over Time: CIPLA's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1935 | 32,323 | Umang Vohra | https://www.cipla.com |
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.
Cipla Limited Fundamentals Summary
CIPLA fundamental statistics | |
---|---|
Market cap | ₹1.20t |
Earnings (TTM) | ₹37.08b |
Revenue (TTM) | ₹251.16b |
32.4x
P/E Ratio4.8x
P/S RatioIs CIPLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CIPLA income statement (TTM) | |
---|---|
Revenue | ₹251.16b |
Cost of Revenue | ₹90.36b |
Gross Profit | ₹160.81b |
Other Expenses | ₹123.72b |
Earnings | ₹37.08b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 45.93 |
Gross Margin | 64.02% |
Net Profit Margin | 14.76% |
Debt/Equity Ratio | 3.8% |
How did CIPLA perform over the long term?
See historical performance and comparison